Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 13 838.75 INR 0.26% Market Closed
Market Cap: 177.6B INR
Have any thoughts about
Neuland Laboratories Ltd?
Write Note

Relative Value

The Relative Value of one NEULANDLAB stock under the Base Case scenario is 7 304.69 INR. Compared to the current market price of 13 838.75 INR, Neuland Laboratories Ltd is Overvalued by 47%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NEULANDLAB Relative Value
Base Case
7 304.69 INR
Overvaluation 47%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
1
vs Industry
21
Median 3Y
2.7
Median 5Y
2.1
Industry
2.5
Forward
10.2
vs History
1
vs Industry
13
Median 3Y
25.4
Median 5Y
26.8
Industry
21.8
Forward
59.5
vs History
1
vs Industry
11
Median 3Y
21.4
Median 5Y
17.2
Industry
16.1
vs History
11
vs Industry
3
Median 3Y
124.4
Median 5Y
80.8
Industry
23.8
vs History
1
vs Industry
8
Median 3Y
3.5
Median 5Y
2.5
Industry
2.1
vs History
1
vs Industry
19
Median 3Y
2.7
Median 5Y
2.2
Industry
2.7
Forward
10.1
vs History
1
vs Industry
15
Median 3Y
5.8
Median 5Y
5.1
Industry
5.2
vs History
1
vs Industry
17
Median 3Y
13.3
Median 5Y
12.9
Industry
13.5
Forward
40.8
vs History
1
vs Industry
17
Median 3Y
18.2
Median 5Y
17
Industry
16.8
Forward
46.7
vs History
1
vs Industry
11
Median 3Y
21.1
Median 5Y
18.1
Industry
15.2
vs History
1
vs Industry
5
Median 3Y
51.8
Median 5Y
53.4
Industry
19.3
vs History
1
vs Industry
14
Median 3Y
2.6
Median 5Y
1.7
Industry
1.9

Multiples Across Competitors

NEULANDLAB Competitors Multiples
Neuland Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
178.5B INR 11.7 63.8 42.8 50.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/E Multiple
Earnings Growth P/E to Growth
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
Average P/E: 35.8
63.8
101%
0.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
Average EV/EBITDA: 417.8
42.8
80%
0.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Neuland Laboratories Ltd
NSE:NEULANDLAB
Average EV/EBIT: 1 815.2
50.6
77%
0.7
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Discover More
Back to Top